Do not swap an EMR to fix marketing
PatientNow is quote-only in two editions: Essentials for aesthetic and cash-pay practices, and Pro for practices needing full EMR, labs and insurance processing. Around the clinical core sit practice management, payments, an Insights hub, RxPhoto for clinical documentation and Recura AI for growth automation, with add-on availability varying by package and edition.
The clinical record is the reason to own it, and it is the last thing you should move. It is what you are audited on, it holds your photography and your consent history, and a migration puts all of that at risk to solve a problem that lives somewhere else entirely.
What happens to marketing inside a clinical suite
When marketing is one module in an EMR platform, it competes for roadmap attention with clinical compliance, labs, insurance and charting, and it loses that competition most quarters. That is not a criticism of the vendor. It is what prioritisation looks like when the same team owns a regulated clinical record and a growth tool.
The practical effect is a marketing module that does the obvious things adequately and rarely gets sharper.
A growth layer that never touches the chart
OpsWyse runs consult follow-up, the treatment-plan chase and the win-back. It segments by what the patient did, drafts each message in your voice, and puts an approval step before anything reaches a patient, which matters more in aesthetics than in most categories.
It holds no clinical data, does not read or write the EMR, and has no opinion about your photography or your labs. PatientNow keeps every part of that. If Recura is already doing the growth job well for you, this comparison is not for you.
The boundary, stated precisely
Wysera holds no clinical data. It does not read the chart, does not write to the chart, does not store clinical photography, and has no interface to labs or e-prescribing. The records that make PatientNow the system you are audited on stay entirely inside PatientNow.
What it works with is enquiries and contact records: who asked about a treatment, what they asked about, whether anyone replied, when they last came in. That is a deliberately narrow surface, and narrow is the point. A growth layer that needs access to the clinical record to function is a growth layer that has just expanded your compliance surface for a marketing outcome.
Consult to treatment is the expensive gap
In aesthetics the consult is the moment of highest intent and the follow-up after it is usually the weakest link in the operation. Someone comes in, discusses a plan, leaves to think about it, and then the practice has no system for the fourteen days in which they decide. A reminder is not a follow-up; it addresses a booking, not a decision.
OpsWyse runs that window as structured work. Playbooks hold the sequence, the Wyse Agent drafts each step on a tick schedule with a per-iteration audit trail, and the Voice Dialer queues the ones worth a call with one-tap disposition so the outcome gets recorded rather than remembered. Every message waits for approval, which in aesthetics is not an optional nicety.
On Recura, honestly
PatientNow ships Recura AI for growth automation, and comparing against a module you have not used is how comparison pages lose credibility. So here is the honest framing rather than a claimed verdict: Recura is growth automation built by a team whose primary obligation is a regulated clinical record, and Wysera is a growth layer built by a team with no other obligation at all.
That difference shows up in roadmap attention over years rather than in a feature table today. If Recura is already producing consults for you, the correct decision is to keep it and close this page. If marketing has quietly become the module nobody has opened in six months, that is the situation this is for.
What changes operationally, and what does not
Nothing migrates. No patient records move, no photography moves, no integration with labs or insurance is touched, and PatientNow remains the only system with the chart. The setup work is connecting the enquiry sources, your web forms and paid lead forms, and defining the approval rules.
What changes is that someone, or something, is now accountable for the fourteen days after a consult and the fourteenth month after a last visit. Those are the two windows where aesthetics revenue leaks, and neither is a clinical problem. More on the wider stack in our marketing guide for med spas and the med spa overview.
Understanding a two-edition quote
PatientNow is quoted in two editions, Essentials for aesthetic and cash-pay practices and Pro for practices needing full EMR, labs and insurance processing, with add-on availability varying by package and edition. That last clause is where quotes diverge, so get the add-on list attached to your specific edition in writing.
The questions that matter: which add-ons are included at your edition rather than available at it, what each excluded one costs, and what changes if you move between editions later. An EMR is a long commitment and the edition boundary is the part that determines what you can add without a renegotiation.
Why the clinical boundary is the point, not a limitation
It would be easy to present Wysera holding no clinical data as a missing feature. It is the opposite. An aesthetics practice already carries the compliance weight of an EMR with photography, consent records and in some editions labs and insurance data. Adding a marketing tool that also touches that material doubles the number of systems that matter when something goes wrong.
Wysera holds enquiry and contact data: who asked about what, what was sent, what happened next. That is all outreach needs. PatientNow remains the only system with the chart, which keeps your compliance story simple and is also why nothing here requires a migration or a data-processing conversation about clinical records.